Founded in 1979 Vision: Founded in 1986 Mission:

We push the Aurobindo's mission is to

Pharmaceutical company Headquartered in Hyderabad
become the most valued
based in Bangalore boundaries of science Leading global pharmaceutical pharmaceutical partner to
A part of AstraZeneca Group, to deliver life-changing company producing oral and the world pharma
which is one of the worlds medicines. injectable generic formulations fraternity by continuously
PRODUCT LINES: and active pharmaceutical researching, developing
leading pharmaceutical
Cardiovascular, ingredients and manufacturing a wide
companies range of pharmaceutical
Engaged in the manufacture Infection ,Diabetes Among the top 15 generics
,Oncology products that comply with
and marketing of companies by sales in Europe the highest regulatory
,Gastrointestinal Ranked as #7 prescription
pharmaceutical products in the standards.
PRODUCT LINE:
,Respiratory, supplier in the US as per IMS Neurosciences,
country
Present in seven crucial areas Anaesthetic total prescriptions dispensed Cardiovascular, Anti-
Mr. D. E. Udwadia, as at March, 2016 retroviral,
of healthcare - Cardiovascular, SSP/Cephalosporin,
Chairman
Diabetes, Oncology, Gastroenterological,
Mr. Sanjay Share Holding Pattern
Respiratory & Inflammation, Controlled substances,
Murdeshwar,
Infection,
Share Local Anesthesia
Holding Pattern and
(%) Anti-diabetics,
Managing Director Dr. Murali K. Respiratory,
Divi :
Maternal Healthcare Ophthalmic,
Chairman
Penem. and MD
N.V.Ramana :Executive
Listed on both BSE & Director
NSE Listed on both BSE & NSE

Revenue (INR
Cr) 570.5 Revenue (INR
Cr) 9349
Employees 1587
Employees 15000+
Book Value 62.81
Book Value 120.6
EPS 2.10
Foreign Promoters Mutual Funds Promoters FIIs Mutual Funds EPS 33.9
FIIs Non Institutions PAT (INR Cr) 5.26 General Public Others
PAT (INR Cr) 1619
 Founded in 1984 Vision: Founded in 1990 Strategy:
To become a discovery Business Strategy is based
Headquarters at Hyderabad R & D is its prime fundamental
on three global drives :
It operates in three segments : led global Manufacturing Facilities in customers,
Global Generics, pharmaceutical Hyderabad and Vishakapatnam Environment and
Pharmaceutical services and company Both the facilities are engaged communities.
PRODUCT LINES: in manufacturing APIs and Our endeavour is to
Active ingredients and proprietary
Global Generics, intermediaries for Generics, respond to these by
products
Biologics, Active Building blocks for Peptides continuously evolving
Manufacturing facilities are in various aspects of our
pharmaceutical and Nucleotides, Caretenoids
Hyderabad, Beijing, UK and operations, products,
ingredients, Custom and Chiral Ligands
USA supply chain
PRODUCT LINE:and our
Pharmaceutical engagements
Generics, with the
Intermediaries,
Has over 190 medications,60
services and communities.
Protected Amino acids,
APIs for Drug Manufacture,
proprietary products Chiral synthesis,
diagnostic kits, critical care Caretonoids and
and biotechnology products K.Satish Reddy, Shareholding pattern (%) Neutraceuticals
Shareholding Pattern(%) Chairman
Dr. Murali K. Divi :
G.V.Prasad, Co- Chairman and Managing
Chairman and CEO Director
N.V.Ramana : Executive
Listed on both BSE & Director
NSE Listed on both BSE &
Revenue (INR NSE
Cr) 10452.5 Revenue (INR
Cr) 3816
Employees 21669
Employees 9481
BV per share
(Rs.) 750 BV per Share
Promoter's Holding Mutual funds
Promoter's Holding Mutual funds ( Rs.) 134
FII EPS (Rs.) 117
FII Others EPS 32
PAT (INR Cr) 1354.5
PAT (INR Cr) 1107.7
Common Size P&L Statement
INFERENCES (As a
Common Size P&L Statement percentage of total
revenue):
140.00%
Net revenue hasnt shown
120.00%
significant changes for any
company.
100.00%
Cost of materials
consumed has decreased
80.00% significantly for Divis lab
and torrent pharma.
60.00% Employee benefit
expenses has shown
40.00% significant increase in
Dr.Reddys but decreased
20.00% significantly for Torrent
pharma.
0.00%
Finance costs has shown
significant increase in
-20.00%
Aurobindo Pharma but
decreased significantly for
-40.00%
Torrent pharma.
Net revenue from operations
Total expenses
Cost of material consumed
PBT
Employee benefit expenses
Net profit for the year
Finance costs
Total expenses has
decreased sharply for Torrent
Common Base P&L Statement
INFERENCES:
Common Base P&L Statement Net revenue from
3.50 operations has shown more
than 50% increase for Torrent
3.00 pharma while it has
decreased only for Sun
2.50 Pharma.
Cost of material consumed
2.00 has decreased for Dr.Reddys,
Biocon, Sun Pharma while it
1.50 has increased by 30% for
Astrazenca.
1.00 Employee benefit
expenses has decreased
0.50 only for Sun Pharma.
Finance costs has increased
0.00 by 70% for Aurobindo Pharma
while only Sun Pharma has
-0.50 shown a decrease.
Total expenses has
Net revenue from operations Cost of material consumed Employee benefit expenses Finance costs decreased only for Sun
Total expenses PBT Net profit for the year Pharma while all other
Common Size Balance Sheet
INFERENCES:
Common Size Balance Sheet Reserves and surplus has
increased significantly for
90.00%
Granules India and Torrent
80.00%
Pharma while it has decreased
only for Biocon.
70.00% Long term borrowings has
decreased significantly for
60.00%
Aurobindo Pharma, Granules
India and Torrent Pharma.
50.00%
Short term borrowings has
40.00% decreased for all companies
except for Biocon and Granules
30.00% India.
Trade Payables and tangible
20.00%
assets has decreased
10.00%
significantly for Granules India.
Long term loans and
0.00% advances has decreased
Reserves & Surplus Long term borrowings Short term borrowings sharply for Biocon India.
Trade Payables Tangible assets Long term loans and advances Trade receivables has
Inventories Trade receivables Cash and Bank Balances
Shortterm loans and advances increased significantly for
Common Base Balance Sheet
INFERENCES:
Common Base Balance Sheet Reserves and Surplus have
5.00 increased significantly for
Aurobindo, Divis Lab, Biocon
4.50
and Torrent pharma.
4.00
Long term borrowings have
increased more than 10 times
3.50 for Biocon.
Short term borrowings ha
3.00

2.50

2.00

1.50

1.00

0.50

0.00

Reserves & Surplus Long term borrowings Short term borrowings

Trade Payables Tangible assets Long term loans and advances
Inventories Trade receivables Cash and Bank Balances
Shortterm loans and advances
 Current Ratio
Significant inferences (*Industry average = 2.4)
Biocon is above industry average of 2.4
Torrent and Dr.Reddys with an average of 2.0
are close to industry average
Astra Zeneca and Granules with an average of
1.2 and 1.4 are consistently below Industry
average
Aurobindo rose from 1.0, 5 years back to 1.5
but still below industry average
Divis labs has consistently increased from 3.0
to 6.0 showing assets being caught up in high
inventory
Sun pharma has shown an alarmingly
decreasing trend

*Above series shows 2012 to 2016 data (right to left)

 Quick Ratio
Significant inferences (*industry average = 1.0)
Trends are similar to Current ratio
Biocon, Dr. Reddys and Torrent Pharma have a
QR higher than industry average of 1.0
Aurobindo and Granules have a QR close to
Industry average
Astro Zenecas QR has shown a haphazard
upward trend but still below industry average
Sun Pharmas QR has significantly fallen over
the years
Divis labs has a sudden surge in Cash ratio
over past 2 years

*Above series shows 2012 to 2016 data (right to left)

Other Short term Solvency
Ratios
 Debt to Equity Ratio
Significant inferences (*industry average = 0.6)
Divis labs and Dr. Reddys have significantly
lower DE ratio and the trend is decreasing. i.e
they are raising more equity and reducing debt
Aurobindo (except for 2015) is around DE ratio
of 0.5
Astra Zenecas average is almost close to 0.6
since last 3 years
Biocon has consistently been at 0.3 significantly
lower than industry average
Sun Pharma has increased its debt in 2014 but
again moving towards its average of 0.3

*Above series shows 2012 to 2016 data (right to left)

Other long term ratios